You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 12, 2026

Claims for Patent: 10,258,661

✉ Email this page to a colleague

Summary for Patent: 10,258,661

Title:	Method for extracting and refining alkaloids from ipecac
Abstract:	Provided is a method for extracting and refining alkaloids from ipecac, comprising: (1) grinding ipecac, adding acidic methanol/ethanol solution for extraction, obtaining an extraction solution A, concentrating under a reduced pressure, and obtaining a concentrated solution B; (2) using reversed-phase polymer filler J for adsorption, and performing desorption by washing with water, collecting a washing solution C, eluting with an alcoholic solution E and collecting a desorption solution D; (3) injecting the washing solution C and the desorption solution D into a preparative high performance liquid chromatograph for separation and purification respectively, to collect a solution G, and a solution H and a solution I respectively; and (4) concentrating the solutions G, H and I, which are then subjected to reversed-phase polymer filler K for adsorption respectively; eluting them respectively after adsorption with an alcoholic solution F; concentrating obtained eluates to dryness; and then performing vacuum drying.
Inventor(s):	Weizhen DONG, Jianhong CHANG
Assignee:	CHENGDU HERBPURIFY Co Ltd
Application Number:	US15/543,204

Details for Patent 10,258,661

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	ARALAST, ARALAST NP	alpha-1-proteinase inhibitor (human)	For Injection	125039	December 23, 2002	10,258,661	2036-09-23
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	October 26, 2009	10,258,661	2036-09-23
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	April 01, 2011	10,258,661	2036-09-23
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326	August 20, 2020	10,258,661	2036-09-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,258,661

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2017067366	⤷ Get Started Free
United States of America	2017368126	⤷ Get Started Free
China	105384737	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.